Taxotere (Docetaxel) is a chemotherapy drug manufactured and marketed by Sanofi-Aventis. Doctors prescribe the drug to treat the majority of breast cancer cases in the U.S. The treatment plan for Taxotere is once every three weeks, unlike Paclitaxel, a drug in the same class, which is weekly and just as effective.

The Taxotere lawsuit states that Sanofi-Aventis failed to warn patients and physicians of the increased risks of permanent alopecia (loss of hair) through the use of Taxotere during chemotherapy. Sanofi-Aventis warned other countries about alopecia risk but did not warn women in the U.S. If properly warned of the risks associated with Taxotere, patients would have been prescribed a different chemotherapy drug that did not result in permanent hair loss.

The Gabrielli Firm is currently accepting Taxotere cases in all 50 states. If you or somebody you know was injured by Taxotere, you should contact our lawyers immediately for a free case consultation.